Morris R G, Frewin D B, Saccoia N C, Goldsworthy W L, Jeffries W S, McPhee A J
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville South, South Australia.
Eur J Clin Pharmacol. 1990;39(4):359-63. doi: 10.1007/BF00315410.
We have examined the current state of interference by digoxin-like immunoreactive substance(s) (DLIS) in 10 commercially available digoxin assay methods, ie 5 radioimmunoassays (RIA) and 5 non-radioactive immunoassays. Fifty-five specimens of maternal venous blood (30 from third trimester pregnancy and 25 at delivery) and 32 cord samples from their offspring were tested (none of the subjects being medicated with digoxin). The results demonstrated a wide range of DLIS interference with values up to 1.1 micrograms.l-1 being obtained in the cord blood specimens. Of the methods tested the "Coat-a Count" RIA (Diagnostic Products Corporation) and the EMIT column method (Syva) run on the Cobas MIRA (Roche) consistently showed the least interference with respect to all 3 sources of specimens. The Delfia Method (LKB/Wallac) consistently showed the greatest crossreactivity with DLIS. The present study thus demonstrates that DLIS interference persists in several commercial digoxin methods and suggests that the use of data obtained from such methods may compromise patient management.
我们已检测了地高辛样免疫反应物质（DLIS）对10种市售地高辛检测方法的干扰现状，即5种放射免疫分析法（RIA）和5种非放射性免疫分析法。检测了55份孕妇静脉血标本（30份来自妊娠晚期，25份来自分娩时）及其32份脐带血标本（所有受试者均未服用地高辛）。结果表明，DLIS干扰范围广泛，脐带血标本中测得的值高达1.1微克·升⁻¹。在所检测的方法中，“Coat-a Count”RIA（诊断产品公司）以及在Cobas MIRA（罗氏公司）上运行的EMIT柱法（希瓦公司）对所有3种标本来源始终显示出最小的干扰。Delfia法（LKB/瓦拉公司）始终显示出与DLIS的交叉反应性最强。因此，本研究表明，DLIS干扰在几种市售地高辛检测方法中仍然存在，并提示使用这些方法获得的数据可能会影响患者的治疗管理。
